Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis

Background: WHO-recommended second-line antiretroviral therapy (ART) of a pharmacologically enhanced (boosted) protease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs) might be compromised by resistance. Results of the 96 week SECOND-LINE randomised trial showed tha...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Boyd, M.A., Moore, C.L., Molina, J.-M., Wood, R., Madero, J.S., Wolff, M., Ruxrungtham, K., Losso, M., Renjifo, B., Teppler, H., Kelleher, A.D., Amin, J., Emery, S., Cooper, D.A.
Formato: JOUR
Materias:
abacavir
didanosine
emtricitabine
lamivudine
lopinavir
raltegravir
ritonavir
RNA directed DNA polymerase
RNA directed DNA polymerase inhibitor
stavudine
tenofovir
zidovudine
2',3' dideoxynucleoside derivative
anti human immunodeficiency virus agent
adult
aged
antiviral resistance
Article
female
gene mutation
genetic algorithm
genotype
genotypic sensitivity score
highly active antiretroviral therapy
human
Human immunodeficiency virus 1 infection
major clinical study
male
multicenter study
priority journal
randomized controlled trial
scoring system
sequence analysis
virus load
Australia
clinical trial
controlled study
drug combination
drug effects
genetics
HIV Infections
Human immunodeficiency virus 1
isolation and purification
medication compliance
middle aged
physiology
psychology
treatment outcome
virology
young adult
Adult
Anti-HIV Agents
Dideoxynucleosides
Drug Resistance, Viral
Drug Therapy, Combination
Female
HIV-1
Humans
Lamivudine
Lopinavir
Male
Medication Adherence
Middle Aged
Ritonavir
South Australia
Tenofovir
Treatment Outcome
Viral Load
Young Adult
Acceso en línea:http://hdl.handle.net/20.500.12110/paper_23523018_v2_n2_pe42_Boyd
Aporte de:
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

Ejemplares similares

Ejemplares similares